Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8818260 | 0.85 | CYP2A6 (0.43) | ACP1CYP2A6TRPM4MEN1KMT2A | |
| SCHEMBL3860367 | 0.82 | ACP1 (0.41) | ACP1CYP2A6MEN1KMT2ARXFP1 | |
| SCHEMBL5253278 | 0.82 | CYP2A6 (0.40) | ACP1CYP2A6TRPM4MEN1KMT2A | |
| SCHEMBL11942308 | 0.82 | ACP1 (0.41) | ACP1CYP2A6MEN1KMT2ARXFP1 | |
| SCHEMBL11803457 | 0.80 | DAO (0.48) | CYP2A6MEN1KMT2ARXFP1CYP1A2 | |
| SCHEMBL10342952 | 0.80 | TDP1 (0.61) | ACP1MEN1KMT2ARXFP1CYP1A2 | |
| SCHEMBL4153655 | 0.79 | TAAR1 (0.47) | CYP2A6CYP1A2CYP3A4CYP2D6HTR2A | |
| SCHEMBL10418726 | 0.77 | CSNK2A1 (0.41) | ACP1CYP2A6MEN1KMT2ACYP1A2 | |
| SCHEMBL4153648 | 0.77 | IFNAR1 (0.45) | ACP1CYP2A6MEN1KMT2ACYP1A2 | |
| SCHEMBL8782470 | 0.77 | NQO2 (0.59) | TRPM4MEN1KMT2ACYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860636-B1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2024107783-A2 | NOVEL MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
| CN-107406414-B | (piperidin-3-yl) (naphthalen-2-yl) methanone derivatives as inhibitors of histone demethylase KDM2B for the treatment of cancer | 基因泰克公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3860636-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | Disc Medicine, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-112996529-A | Matriptase 2 inhibitor and application thereof | 迪斯克医药公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020072580-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-2010178-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-2010519-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120655-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120688-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-5132421-A | 2-naphthyl-carbapenem intermediates | MERCK & CO., INC. (US) | 1992-07-21 | — | — | US | disclosed |
| US-5132422-A | 2-naphthyl-carbapenem intermediates | MERCK & CO., INC. (US) | 1992-07-21 | — | — | US | disclosed |
| EP-0466253-A1 | 2-naphthyl-carbapenems | MERCK & CO. INC. (US) | 1992-01-15 | — | — | EP | disclosed |
| EP-0466254-A1 | 2-naphthyl-carbapenems | MERCK & CO. INC. (US) | 1992-01-15 | — | — | EP | disclosed |
| US-5032587-A | Antibiotics, carbapenicillins | MERCK & CO., INC. (US) | 1991-07-16 | — | — | US | disclosed |
| US-5006519-A | 2-naphthyl-carbapenem antibacterial agents | MERCK & CO., INC. (US) | 1991-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | ACP1 2877/4885CYP2A6 2040/4885TRPM4 3517/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | ACP1 2877/4885CYP2A6 2040/4885TRPM4 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.